Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2476
Source ID: NCT01885260
Associated Drug: Isis-Gcgrrx - Dose Level 1
Title: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: ISIS-GCGRRx - Dose Level 1|DRUG: ISIS-GCGRRx - Dose Level 2|DRUG: Placebo
Outcome Measures: Primary: The effect of ISIS-GCGRRx on serum fructosamine, Change from Baseline to Week 14, 14 Weeks | Secondary: The safety of ISIS-GCGRRx, By determining the incidence, severity, dose-relationship adverse effects, and changes in laboratory evaluations, 25 Weeks|The tolerability of ISIS-GCGRRx, By determining the incidence, severity, dose-relationship adverse effects, and changes in laboratory evaluations, 25 Weeks
Sponsor/Collaborators: Sponsor: Ionis Pharmaceuticals, Inc.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 77
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2013-07
Completion Date: 2014-11
Results First Posted:
Last Update Posted: 2016-07-04
Locations: Isis Investigational Site, Birmingham, Alabama, 35216, United States|Isis Investigational Site, Muscle Shoals, Alabama, 35662, United States|Isis Investigational Site, Anaheim, California, 92801, United States|Isis Investigational Site, Chino, California, 91710, United States|Isis Investigational Site, Los Angeles, California, 90057, United States|Isis Investigational Site, Deland, Florida, 32720, United States|Isis Investigational Site, Ft. Lauderdale, Florida, 33306, United States|Isis Investigational Site, Miami, Florida, 33143, United States|Isis Investigational Site, Marietta, Georgia, 30066, United States|Isis Investigational Site, Las Vegas, Nevada, 89101, United States|Isis Investigational Site, Cincinnati, Ohio, 45245, United States|Isis Investigational Site, Oklahoma City, Oklahoma, 73103, United States|Isis Investigational Site, Eugene, Oregon, 97404, United States|Isis Investigational Site, Corpus Christi, Texas, 78404, United States|Isis Investigational Site, Katy, Texas, 77450, United States|Isis Investigational Site, Salt Lake City, Utah, 84107, United States|Isis Investigational Site, Renton, Washington, 98057, United States|Isis Investigational Site, Spokane, Washington, 99202, United States|Isis Investigational Site, Lenasia South, Gauteng, 1829, South Africa|Isis Investigational Site, Soweto, Gauteng, 1818, South Africa|Isis Investigational Site, Durban, KwaZulu-Natal, 4091, South Africa|Isis Investigational Site, Cape Town, Western Cape, 7700, South Africa|Isis Investigational Site, Parow, Cape Town, Western Cape, 7500, South Africa|Isis Investigational Site, Western Cape, 7130, South Africa
URL: https://clinicaltrials.gov/show/NCT01885260

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress